Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading

Quest Diagnostics has recently launched a groundbreaking prostate cancer test that aims to improve the diagnosis and grading of this disease.

 

This innovative lab service utilizes Envision Science's exclusive biomarkers and technology, with the ultimate goal of enhancing the accuracy of prostate cancer diagnosis and grading.

The launch of this new test was announced by Quest Diagnostics, the leading provider of diagnostic information services, in collaboration with Envision Sciences, an Australian-based clinical diagnostics company specializing in biomarker-based cancer tests for tissue and blood samples.

 

Specifically designed to address the urgent clinical need for better identification and differentiation of potentially aggressive cases of prostate cancer in men, this tissue-based test service is expected to make significant advancements in improving patient outcomes.